Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Exosomal and non-exosomal miRNAs may serve as biomarkers for HCV-related cirrhosis, liver canceron October 11, 2021 at 6:48 am
Oncotarget published "Exosomal and non-exosomal miRNA expression levels in patients with HCV-related cirrhosis and liver cancer" which reported that patients with HCV-related cirrhosis are at risk for ...
- New artificial intelligence offers hope for liver cancer patients with less than 13 percent chance of survivalon October 11, 2021 at 5:42 am
Researchers at King's College Hospital and Queen Mary University of London have shown that a new computer-based algorithm can rank drugs used to treat primary liver cancer, based on their efficacy in ...
- Join the American Liver Foundation's Associate Board to support those affected by liver diseaseon October 11, 2021 at 3:26 am
The GNY Associate Board is a group of young professionals who are determined to educate young professionals about liver health, create funds for patient services and research on liver disease, ...
- Las Vegas girl to receive life-saving liver transplant from motheron October 10, 2021 at 10:16 pm
A little girl in Las Vegas is getting a second chance at life after being diagnosed with an extremely rare liver disease. 5-year-old Lucy Forte has biliary atresia. The illness blocks bile flow from ...
- The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease.on October 10, 2021 at 10:09 pm
Hepatitis D Virus (HDV) infection is vanishing in Italy. It is therefore believed that hepatitis D is no longer a medical problem in the domestic population of the country but remains of concern only ...
- Suppression of Serotonin Signal Helps Improve Diabetes and Fatty Liver Diseaseon October 10, 2021 at 5:27 pm
A joint research team from the Korea Advanced Institute of Science and Technology (KAIST) and the Seoul National University Bundang Hospital confirmed that diabetes and fatty liver disease can be ...
- In the quest for a liver transplant, patients are segregated by prior alcohol useon October 10, 2021 at 6:08 am
Many transplant centers require people with alcohol-related liver disease to remain sober for half a year, before becoming eligible for the waiting list for a liver. But this thinking may be changing.
- Runaway algae growth causes neurological problems for those with liver diseaseon October 5, 2021 at 4:31 am
Researchers from the Center for Oceans and Human Health on Climate Change Interactions (OHHC2I) have leveraged their collective expertise in environmental health sciences to reveal additional health ...
- COVID-19 Cancels Liver Disease Patients’ Procedureson October 1, 2021 at 7:18 am
More than half of advanced liver disease patients have had procedures canceled due to the COVID-19 pandemic, according to a recent survey.
via Bing News